First human tests: how a new liver drug behaves in damaged organs
NCT ID NCT05917938
Summary
This early study tested how a new drug for fatty liver disease moves through and is processed by the body in people with different levels of liver damage. It involved 33 adults, some with liver problems and some with healthy livers, who each received one injection of the drug. The main goal was to see if the drug is safe and behaves differently in people with impaired liver function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APEX Research
München, 81241, Germany
-
Cardiomedicum Sp. z o.o.
Krakow, 30-002, Poland
-
Summit Clinical Research s.r.o.
Bratislava, 83101, Slovakia
-
Summit Clinical Research s.r.o.
Malacky, 901 22, Slovakia
-
Uniwersyteckie Centrum Kliniczne (UCK)
Gdansk, 80-214, Poland
Conditions
Explore the condition pages connected to this study.